NICE draft guidance recommends sapropterin for children with rare inherited metabolic condition phenylketonuria
NICE has today (25 February 2021) issued draft guidance for public consultation which recommends sapropterin (also called Kuvan and made by BioMarin) for treating phenylketonuria (PKU) in children aged up to 18.
-
NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE
NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more data can be collected while patients can access the treatment.
-
Skin cancer drug recommended for routine NHS use
An appeal period has now opened until 26 February 2021.
-
NICE recommends treatment options for severe pregnancy sickness in new draft guidance
Nausea and vomiting, often referred to as morning sickness, is common in pregnancy. Close to 80% of pregnant women experience these symptoms, with most conditions improving or stopping completely by around 16 to 20 weeks.
